Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Laurent Garderet, Myriam Labopin, Norbert Claude Gorin, Emmanuelle Polge, André Baruchel, Giovanna Meloni, Juan Ortega, Jaak Vossen, Donald Bunjes, Guy Leverger, Didier Blaise, Augustin Ferrant, Mats Brune, Eric Dore, Helmut Gadner, Felix Zintl, Isaac Yaniv, Giorgio Dini, Francesco Frassoni

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalBlood
Volume105
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Leukemia, Megakaryoblastic, Acute
Hematopoietic Stem Cell Transplantation
Stem cells
Bone
Retrospective Studies
Irradiation
Transplants
Autografts
Autologous Transplantation
Homologous Transplantation
Recurrence
Down Syndrome
Mortality
Leukemia
Stem Cells
Survival Rate
Bone Marrow
Survival
Therapeutics
Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission : A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). / Garderet, Laurent; Labopin, Myriam; Gorin, Norbert Claude; Polge, Emmanuelle; Baruchel, André; Meloni, Giovanna; Ortega, Juan; Vossen, Jaak; Bunjes, Donald; Leverger, Guy; Blaise, Didier; Ferrant, Augustin; Brune, Mats; Dore, Eric; Gadner, Helmut; Zintl, Felix; Yaniv, Isaac; Dini, Giorgio; Frassoni, Francesco.

In: Blood, Vol. 105, No. 1, 01.01.2005, p. 405-409.

Research output: Contribution to journalArticle

Garderet, L, Labopin, M, Gorin, NC, Polge, E, Baruchel, A, Meloni, G, Ortega, J, Vossen, J, Bunjes, D, Leverger, G, Blaise, D, Ferrant, A, Brune, M, Dore, E, Gadner, H, Zintl, F, Yaniv, I, Dini, G & Frassoni, F 2005, 'Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)', Blood, vol. 105, no. 1, pp. 405-409. https://doi.org/10.1182/blood-2004-03-1103
Garderet, Laurent ; Labopin, Myriam ; Gorin, Norbert Claude ; Polge, Emmanuelle ; Baruchel, André ; Meloni, Giovanna ; Ortega, Juan ; Vossen, Jaak ; Bunjes, Donald ; Leverger, Guy ; Blaise, Didier ; Ferrant, Augustin ; Brune, Mats ; Dore, Eric ; Gadner, Helmut ; Zintl, Felix ; Yaniv, Isaac ; Dini, Giorgio ; Frassoni, Francesco. / Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission : A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). In: Blood. 2005 ; Vol. 105, No. 1. pp. 405-409.
@article{3249bbe2e1d842559faed9793d127c32,
title = "Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)",
abstract = "Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97{\%} and 70{\%}; bone marrow as stem cell source, 74{\%} and 43{\%}. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63{\%} and 42{\%}; bone marrow as stem cell source, 95{\%} and 69{\%}. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90{\%} and 100{\%}; 3-year treatment-related mortality (TRM) rate, 3{\%} and 8{\%}; relapse rate, 45{\%} and 64{\%}; leukemia-free survival (LFS) rate, 52{\%} and 27{\%}; overall survival (OS) rate, 61{\%} and 30{\%}. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95{\%} and 90{\%}; TRM, 0{\%} and 26{\%}; relapse rate, 34{\%} and 28{\%}; LFS, 66{\%} and 46{\%}; OS, 82{\%} and 43{\%}). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.",
author = "Laurent Garderet and Myriam Labopin and Gorin, {Norbert Claude} and Emmanuelle Polge and Andr{\'e} Baruchel and Giovanna Meloni and Juan Ortega and Jaak Vossen and Donald Bunjes and Guy Leverger and Didier Blaise and Augustin Ferrant and Mats Brune and Eric Dore and Helmut Gadner and Felix Zintl and Isaac Yaniv and Giorgio Dini and Francesco Frassoni",
year = "2005",
month = "1",
day = "1",
doi = "10.1182/blood-2004-03-1103",
language = "English",
volume = "105",
pages = "405--409",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission

T2 - A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

AU - Garderet, Laurent

AU - Labopin, Myriam

AU - Gorin, Norbert Claude

AU - Polge, Emmanuelle

AU - Baruchel, André

AU - Meloni, Giovanna

AU - Ortega, Juan

AU - Vossen, Jaak

AU - Bunjes, Donald

AU - Leverger, Guy

AU - Blaise, Didier

AU - Ferrant, Augustin

AU - Brune, Mats

AU - Dore, Eric

AU - Gadner, Helmut

AU - Zintl, Felix

AU - Yaniv, Isaac

AU - Dini, Giorgio

AU - Frassoni, Francesco

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.

AB - Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.

UR - http://www.scopus.com/inward/record.url?scp=19944426092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426092&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-1103

DO - 10.1182/blood-2004-03-1103

M3 - Article

C2 - 15191953

AN - SCOPUS:19944426092

VL - 105

SP - 405

EP - 409

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -